Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internat…
Biotechnology
US, Novato [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 17.59 | 2.43 | 2.06 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | 1102.13 | -5.20 | 0.43 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 276.05 | 1.66 | 0.44 | |
| Cash | -19.53 | 4.96 | 6.17 | |
| Capex | -100.00 | -0.16 | 0.00 | |
| Free Cash Flow | 397.17 | -2.42 | 0.49 | |
| Revenue | -5.63 | 1.29 | 1.37 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q3 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | -14.68 | 0.76 | 0.89 | |
| Operating Margin | -2.67 | -1.52 | -1.48 | |
| ROA | -1.27 | -0.13 | -0.13 | |
| ROE | 75.83 | -1.22 | -5.03 | |
| ROIC | 93.92 | -0.16 | -2.61 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of RARE is permitted for members.
5
Growth
The "Growth Entry" for the Focus of RARE is permitted for members.
6
Leverage & Liquidity